Cargando…
The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma
BACKGROUND: Sorafenib and transarterial chemoembolization (TACE) are recommended therapies for advanced hepatocellular carcinoma (HCC), but their combined efficacy remains unclear. METHODS: Between August 2004 and November 2014, 104 patients with BCLC stage B/C HCC were enrolled at the Affiliated Tu...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5596482/ https://www.ncbi.nlm.nih.gov/pubmed/28899349 http://dx.doi.org/10.1186/s12885-017-3545-5 |
_version_ | 1783263540919926784 |
---|---|
author | Wu, Fei-Xiang Chen, Jie Bai, Tao Zhu, Shao-Liang Yang, Tian-Bo Qi, Lu-Nan Zou, Ling Li, Zi-Hui Ye, Jia-Zhou Li, Le-Qun |
author_facet | Wu, Fei-Xiang Chen, Jie Bai, Tao Zhu, Shao-Liang Yang, Tian-Bo Qi, Lu-Nan Zou, Ling Li, Zi-Hui Ye, Jia-Zhou Li, Le-Qun |
author_sort | Wu, Fei-Xiang |
collection | PubMed |
description | BACKGROUND: Sorafenib and transarterial chemoembolization (TACE) are recommended therapies for advanced hepatocellular carcinoma (HCC), but their combined efficacy remains unclear. METHODS: Between August 2004 and November 2014, 104 patients with BCLC stage B/C HCC were enrolled at the Affiliated Tumor Hospital of Guangxi Medical University, China. Forty-eight patients were treated with sorafenib alone (sorafenib group) and 56 with TACE plus sorafenib (TACE + sorafenib group). Baseline demographic/clinical data were collected. The primary outcomes were median overall survival (OS) and progression-free survival (PFS). Secondary outcomes were overall response rate (ORR) and sorafenib-related adverse events (AEs). Baseline characteristics associated with disease prognosis were identified using multivariate Cox hazards regression. RESULTS: The mean age of the 104 patients (94 males; 90.38%) was 49.02 ± 12.29 years. Of the baseline data, only albumin level (P = 0.028) and Child-Pugh class (P = 0.017) differed significantly between groups. Median OS did not differ significantly between the sorafenib and TACE + sorafenib groups (18.0 vs. 22.0 months, P = 0.223). Median PFS was significantly shorter in the sorafenib group than that in the TACE + sorafenib group (6.0 vs. 8.0 months, P = 0.004). Six months after treatments, the ORRs were similar between the sorafenib and TACE + sorafenib groups (12.50% vs. 18.75%, P = 0.425). The rates of grade III–IV adverse events in sorafenib and TACE + sorafenib groups were 29.2% vs. 23.2%, respectively. TACE plus sorafenib treatment (HR = 0.498, 95% CI = 0.278–0.892), no vascular invasion (HR = 0.354, 95% CI = 0.183–0.685) and Child-Pugh class A (HR = 0.308, 95% CI = 0.141–0.674) were significantly associated with better OS, while a larger tumor number was predictive of poorer OS (HR = 1.286, 95% CI = 1.031–1.604). TACE plus sorafenib treatment (HR = 0.461, 95% CI = 0.273–0.780) and no vascular invasion (HR = 0.557, 95% CI = 0.314–0.988) were significantly associated with better PFS. CONCLUSIONS: Compared with sorafenib alone, combining TACE with sorafenib might prolong survival and delay disease progression in patients with advanced HCC. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-017-3545-5) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5596482 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-55964822017-09-15 The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma Wu, Fei-Xiang Chen, Jie Bai, Tao Zhu, Shao-Liang Yang, Tian-Bo Qi, Lu-Nan Zou, Ling Li, Zi-Hui Ye, Jia-Zhou Li, Le-Qun BMC Cancer Research Article BACKGROUND: Sorafenib and transarterial chemoembolization (TACE) are recommended therapies for advanced hepatocellular carcinoma (HCC), but their combined efficacy remains unclear. METHODS: Between August 2004 and November 2014, 104 patients with BCLC stage B/C HCC were enrolled at the Affiliated Tumor Hospital of Guangxi Medical University, China. Forty-eight patients were treated with sorafenib alone (sorafenib group) and 56 with TACE plus sorafenib (TACE + sorafenib group). Baseline demographic/clinical data were collected. The primary outcomes were median overall survival (OS) and progression-free survival (PFS). Secondary outcomes were overall response rate (ORR) and sorafenib-related adverse events (AEs). Baseline characteristics associated with disease prognosis were identified using multivariate Cox hazards regression. RESULTS: The mean age of the 104 patients (94 males; 90.38%) was 49.02 ± 12.29 years. Of the baseline data, only albumin level (P = 0.028) and Child-Pugh class (P = 0.017) differed significantly between groups. Median OS did not differ significantly between the sorafenib and TACE + sorafenib groups (18.0 vs. 22.0 months, P = 0.223). Median PFS was significantly shorter in the sorafenib group than that in the TACE + sorafenib group (6.0 vs. 8.0 months, P = 0.004). Six months after treatments, the ORRs were similar between the sorafenib and TACE + sorafenib groups (12.50% vs. 18.75%, P = 0.425). The rates of grade III–IV adverse events in sorafenib and TACE + sorafenib groups were 29.2% vs. 23.2%, respectively. TACE plus sorafenib treatment (HR = 0.498, 95% CI = 0.278–0.892), no vascular invasion (HR = 0.354, 95% CI = 0.183–0.685) and Child-Pugh class A (HR = 0.308, 95% CI = 0.141–0.674) were significantly associated with better OS, while a larger tumor number was predictive of poorer OS (HR = 1.286, 95% CI = 1.031–1.604). TACE plus sorafenib treatment (HR = 0.461, 95% CI = 0.273–0.780) and no vascular invasion (HR = 0.557, 95% CI = 0.314–0.988) were significantly associated with better PFS. CONCLUSIONS: Compared with sorafenib alone, combining TACE with sorafenib might prolong survival and delay disease progression in patients with advanced HCC. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-017-3545-5) contains supplementary material, which is available to authorized users. BioMed Central 2017-09-12 /pmc/articles/PMC5596482/ /pubmed/28899349 http://dx.doi.org/10.1186/s12885-017-3545-5 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Wu, Fei-Xiang Chen, Jie Bai, Tao Zhu, Shao-Liang Yang, Tian-Bo Qi, Lu-Nan Zou, Ling Li, Zi-Hui Ye, Jia-Zhou Li, Le-Qun The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma |
title | The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma |
title_full | The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma |
title_fullStr | The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma |
title_full_unstemmed | The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma |
title_short | The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma |
title_sort | safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with bclc stage b/c hepatocellular carcinoma |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5596482/ https://www.ncbi.nlm.nih.gov/pubmed/28899349 http://dx.doi.org/10.1186/s12885-017-3545-5 |
work_keys_str_mv | AT wufeixiang thesafetyandefficacyoftransarterialchemoembolizationcombinedwithsorafenibandsorafenibmonotherapyinpatientswithbclcstagebchepatocellularcarcinoma AT chenjie thesafetyandefficacyoftransarterialchemoembolizationcombinedwithsorafenibandsorafenibmonotherapyinpatientswithbclcstagebchepatocellularcarcinoma AT baitao thesafetyandefficacyoftransarterialchemoembolizationcombinedwithsorafenibandsorafenibmonotherapyinpatientswithbclcstagebchepatocellularcarcinoma AT zhushaoliang thesafetyandefficacyoftransarterialchemoembolizationcombinedwithsorafenibandsorafenibmonotherapyinpatientswithbclcstagebchepatocellularcarcinoma AT yangtianbo thesafetyandefficacyoftransarterialchemoembolizationcombinedwithsorafenibandsorafenibmonotherapyinpatientswithbclcstagebchepatocellularcarcinoma AT qilunan thesafetyandefficacyoftransarterialchemoembolizationcombinedwithsorafenibandsorafenibmonotherapyinpatientswithbclcstagebchepatocellularcarcinoma AT zouling thesafetyandefficacyoftransarterialchemoembolizationcombinedwithsorafenibandsorafenibmonotherapyinpatientswithbclcstagebchepatocellularcarcinoma AT lizihui thesafetyandefficacyoftransarterialchemoembolizationcombinedwithsorafenibandsorafenibmonotherapyinpatientswithbclcstagebchepatocellularcarcinoma AT yejiazhou thesafetyandefficacyoftransarterialchemoembolizationcombinedwithsorafenibandsorafenibmonotherapyinpatientswithbclcstagebchepatocellularcarcinoma AT lilequn thesafetyandefficacyoftransarterialchemoembolizationcombinedwithsorafenibandsorafenibmonotherapyinpatientswithbclcstagebchepatocellularcarcinoma AT wufeixiang safetyandefficacyoftransarterialchemoembolizationcombinedwithsorafenibandsorafenibmonotherapyinpatientswithbclcstagebchepatocellularcarcinoma AT chenjie safetyandefficacyoftransarterialchemoembolizationcombinedwithsorafenibandsorafenibmonotherapyinpatientswithbclcstagebchepatocellularcarcinoma AT baitao safetyandefficacyoftransarterialchemoembolizationcombinedwithsorafenibandsorafenibmonotherapyinpatientswithbclcstagebchepatocellularcarcinoma AT zhushaoliang safetyandefficacyoftransarterialchemoembolizationcombinedwithsorafenibandsorafenibmonotherapyinpatientswithbclcstagebchepatocellularcarcinoma AT yangtianbo safetyandefficacyoftransarterialchemoembolizationcombinedwithsorafenibandsorafenibmonotherapyinpatientswithbclcstagebchepatocellularcarcinoma AT qilunan safetyandefficacyoftransarterialchemoembolizationcombinedwithsorafenibandsorafenibmonotherapyinpatientswithbclcstagebchepatocellularcarcinoma AT zouling safetyandefficacyoftransarterialchemoembolizationcombinedwithsorafenibandsorafenibmonotherapyinpatientswithbclcstagebchepatocellularcarcinoma AT lizihui safetyandefficacyoftransarterialchemoembolizationcombinedwithsorafenibandsorafenibmonotherapyinpatientswithbclcstagebchepatocellularcarcinoma AT yejiazhou safetyandefficacyoftransarterialchemoembolizationcombinedwithsorafenibandsorafenibmonotherapyinpatientswithbclcstagebchepatocellularcarcinoma AT lilequn safetyandefficacyoftransarterialchemoembolizationcombinedwithsorafenibandsorafenibmonotherapyinpatientswithbclcstagebchepatocellularcarcinoma |